Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes trial results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes trial results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes trial results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes trial results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial in your area.
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
29.61
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
21.34
Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
20.06
SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes
20.70
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
26.33
Cardiovascular Outcomes Trial (CVOT)
22.91
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism
28.05
